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Background: Although morbidity and mortality due to ST-segment elevation myocardial infarction (STEMI) has been greatly reduced with the 
advent of primary percutaneous coronary intervention (PCI), patients remain at considerable risk of death and development of congestive heart 
failure (CHF). The complex pathophysiology of STEMI reperfusion has reinforced the need for mechanistically linked biomarkers to improve risk 
stratification and aid in choosing adjuvant therapy. Multiple acute phase angiographic, biochemical and ECG biomarkers have been previously 
identified to quantitate different aspect of this disease process. Therefore, we sought to investigate the most predictive combination of early 
biomarkers as a “biosignature” to predict death and new onset CHF.
Methods: We analyzed 1349 patients from the CASTEMI, EMERALD, AMIHOT-I, AMIHOT-II, and DELTA-MI trials with STEMI<6 hrs who underwent 
primary PCI with: ST-segment recovery, from preceding peak ST-elevation, at last contrast and 240 minutes after LC on 12-lead digital Holter 
monitoring; angiographic post-PCI Thrombolysis in Myocardial Infarction (TIMI) graded flow and perfusion grade; and creatinin-kinase myocardial 
band (CK-MB) peak measurement expressed as multiples of the upper limit of normal (ULN). Variables were entered in multivariable logistic 
regression for their association with the composite endpoint of death or new onset CHF.
Results: After multivariable analysis, post-PCI TIMI graded flow of <3 (OR 1.98, 95% CI 1.07-3.65, p=0.029), ST-segment recovery after 240 
minutes (OR [per 5%] 0.895, 95% CI 0.839-0.955, p=0.0007) and CK-MB peak measurement (OR [per 5x ULN] 1.029, 95% CI 1.004-1.055, 
p=0.022).
Conclusion: In this study, we found that procedural success of primary PCI by post-procedural TIMI 3 flow, myocellular recovery as seen through ST-
segment recovery and myocardial necrosis by CK-MB elevation all provide independent prognostic information to predict death and new onset CHF. 
These findings support the use of multiple biomarkers for robust risk stratification shortly after primary PCI and identification of optimal adjuvant 
treatment to improve clinical outcome.
